The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
Cell · 2025-12 · 188 (26) · 7337-7354
DOI: 10.1016/j.cell.2025.11.033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell, 2025-12. Verfasst von Jean-Philippe Courade und 3 weiteren Autor:innen. Beteiligte Einrichtung: Discoveric bio alpha, Bahnhofstrasse 1, 8808 Pfäffikon, Switzerland. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Amyloid beta-Peptides. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Dementia Research Institute, Alzheimer's Drug Discovery Foundation, Deutsche Forschungsgemeinschaft.
Themen: Demenz
Abstract (Originalsprache)
A marked evolution in Alzheimer's disease (AD) therapy research is ongoing. In this perspective, we highlight emerging outcomes of tau-targeting approaches with disease-modifying potential evidenced by PET-based slowing of tau accumulation and early signs of cognitive benefit. We outline how decades of iterative amyloid β (Aβ)-trial refinement leading to the recent successes of approved anti-Aβ therapies have set the stage for accelerated optimization of next-generation trials. We summarize key learnings from first-generation tau immunotherapies and how these paved the way for early achievements in tau trials, while many challenges remain. Finally, we discuss the back-translation of clinical outcomes into fundamental insights on human tau pathobiology, and we outline challenges and future directions for AD therapy development including combination therapy and targets beyond Aβ/tau. Together, this provides a framework for next-generation AD and tau-therapy development toward increasingly efficient disease-halting interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discoveric bio alpha, Bahnhofstrasse 1, 8808 Pfäffikon, Switzerland.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University…
- Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology…
- Department of Neurosciences, Biomedical Research Institute BIOMED, Hasselt University, Hasselt, Belgium. Electronic address: ilse.dewachter@uhasselt.be.
Förderung
- UK Dementia Research Institute
- Alzheimer's Drug Discovery Foundation
- Deutsche Forschungsgemeinschaft
- EU Joint Programme – Neurodegenerative Disease Research
- Bijzonder Onderzoeksfonds UGent
- Stiftelsen för Gamla Tjänarinnor
- National Institute for Health and Care Research
- Horizon 2020 Framework Programme
Zitieren
APA
Courade, J. P., Zetterberg, H., Höglinger, G. U., & Dewachter, I. (2025). The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau. Cell, 188(26), 7337-7354. https://doi.org/10.1016/j.cell.2025.11.033
Vancouver
Courade JP, Zetterberg H, Höglinger GU, Dewachter I. The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau. Cell. 2025;188(26):7337-7354. doi:10.1016/j.cell.2025.11.033
BibTeX
@article{Courade2025,
author = {Courade, Jean-Philippe and Zetterberg, Henrik and Höglinger, Günter U and Dewachter, Ilse},
title = {The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau},
journal = {Cell},
year = {2025},
volume = {188},
number = {26},
pages = {7337--7354},
doi = {10.1016/j.cell.2025.11.033}
}
EUVIMED